Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 4Lymphoid 3Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 25Lymphoma, Follicular 24Multiple Myeloma 22Lymphoma, B-Cell, Marginal Zone 21Leukemia 21Lymphoma, Non-Hodgkin 19Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Hematologic Neoplasms 16Waldenstrom Macroglobulinemia 15Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 12Congenital Abnormalities 11Burkitt Lymphoma 11Lymphoma, Large-Cell, Immunoblastic 10Mycosis Fungoides 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Sezary Syndrome 8Recurrence 8Hodgkin Disease 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Plasma Cell 6Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6

Interventions

Zoledronic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Denosumab 1CLR1404 1Bortezomib 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blood Protein Disorders × Bortezomib × Other hematologic neoplasm × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡